A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

← catalyst calendar

NCT07693868 · readout in 347 d

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

128estimated

Sites

Country

Netherlands

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-06

actual

When the study began enrolling

Primary completion

2027-08-01

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-08-01

estimated

The whole study's end, after follow-up

First posted

2026-07-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Obesity
Elevated High-sensitivity C-reactive Protein (hsCRP)

Interventions

Drug: NNC6022-0004
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

measured From pre-dose (Day 1) until visit 3 (Day 9)

Part A: Maximum observed plasma concentration (Cmax) of NNC6022-0001 after a single dose

measured From pre-dose (Day 1) until visit 3 (Day 9)

Part B: Number of treatment emergent adverse events (TEAE)

measured From time of dosing (Day 1) to end of study visit (Day 14)

Part C: Number of treatment emergent adverse events

measured From time of dosing (Day 1) to end of study visit (Day 41)

Part D: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

measured From pre-dose (Day 1 or Day 8) to end of visit (Day 5 or Day 12)

Part E: Number of treatment emergent adverse events

measured From time of dosing (Day 1) to end of study visit (Day 13)

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed